Skip to main content
. 2018 Feb 2;9(13):11279–11290. doi: 10.18632/oncotarget.24397

Figure 3. The accumulation of PMN-MDSCs with STAT3 activity in HNSCC patients after CMT.

Figure 3

The results of Nanostring analysis detecting levels of mRNA expression of IL6 (A), IL6R (B), STAT3 (C) in HNSCC patients’ PBMC samples at baseline and after two weeks of CMT (n=6). Percentage of PMN-MDSC (CD14-CD15+CD33+) (D) and M-MDSC (HLA-DRlow/-CD14+CD15-) (E) in HNSCC patients’ PBMCs were analyzed using multcolor flow cytometry. (F) Arginase activity was measured in plasma samples drawn before CMT (baseline), at week 4, and at week 7. Frequencies of pSTAT3+ expression was quantified in CD33+ myeloid population (G), PMN-MDSC (H), and M-MDSC (I) using flow cytometry. Paired student t-test; *p<0.05, **p<0.005, ***p<0.0005.